SynthesisOrphanet journal of rare diseases2026
The prevalence of phenylketonuria (PKU) and hyperphenylalaninemia (HPA) in Iran: a systematic review and meta-analysis.
Synthesis in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPhenylketonuria (PKU) is one of the common Inborn Errors of Metabolism diseases, that is caused by a phenylalanine hydroxylase (PAH) deficiency or cofactor tetrahydrobiopterin. This systematic review and meta-analysis aimed to investigate the prevalence of PKU in Iran.
methodsThe protocol was registered in PROSPERO (CRD42024540811). The MOOSE protocol and the PRISMA guidelines were used. The Web of Sciences, PubMed/ Medline, Sciences Direct, Google Scholar, Scopus, Civilica, IranDoc, and SID databases were searched on 31/03/2024. The I
resultsFinally, 20 studies with 1,992,090 Iranian neonates were included. The prevalence of screen-positive cases was 75.6 (95% CI: 48.1-118.72). The prevalence of confirmed PKU was 16.7 (95% CI: 13.6- 20.5); this prevalence in girls and boys was 15.2 (95% CI: 5.2-44.2) and 9.8 (95% CI: 3.2- 29.8), respectively. 53% of the cases had Hyperphenylalaninemia (HPA). The prevalence of HPA and classical PKU was estimated at 8.9 (95% CI: 5.9-13.41) and 8.0 (95% CI: 5.1-12.59), respectively. Subgroup analysis was performed based on region, province, and study quality to discover the source of heterogeneity. In addition, mixed effects meta-regression was used to find the relationship between continuous variables. Sensitivity analysis showed that the pooled estimate was robust.
conclusionsIt seems that the screening program in Iran was effective and detected almost all PKU cases in the first few days of their lives. This information showed that the PKU prevalence is relatively higher than in most parts of the world, thus their prevalence should be controlled.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.